Jun
2026
Shanghai New International Expo Center
Visit us
stand E2C71, Contract Services

Polpharma

About Us

Polpharma API is a part of Polish leading multinational pharmaceutical group trusted by millions of patients and business partners for almost 90 years.  Polpharma API. Thanks to over 75 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. 

  • Country/Region:
    Poland
  • On CPHI since:
    2015
  • Certificates:
    4
  • Employees:
    5000+
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Contact info
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E2C71, Contract Services

Products Featured at CPHI & PMEC China 2026

  • Acenocoumarol

    Product Acenocoumarol

    Therapeutic Area: Cardiovascular system
    EU DMF 
    Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist
    • Long experience in  in-house commercial manufacturing • No risk of  nitrosoamine presence
  • Acetazolamide

    Product Acetazolamide

    Therapeutic Area: Cardiovascular system 
    EU DMF
    US DMF

    Korean DMF
    Japanese DMF
    CEP available 
    Available also in injectable form Indication: Acetazolamide decreases the pressure in the eye and is used for adjunctive treatment of glaucoma, a condition in which increa...
  • Aripiprazole

    Product Aripiprazole

    Therapeutic Area: Nervous SystemEU DMF availableUS DMF no. 23314 availableCEP available Indication: used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adult...
  • Carbamazepine

    Product Carbamazepine

    Therapeutic Area: Nervous System EU DMF availableUS DMF no. 26266 availableCEP available Indication: Carbamazepine is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia.
  • Carvedilol

    Product Carvedilol

    Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 17060 availableCEP available Indication: Carvedilol is a carbazole derivative acts as anti-hypertensive agent. It is formulated as tablets for oral route of administration. Carvedilol is indicated for the management of essential hypertens...

Polpharma Group Resources (1)

  • Brochure API Product List 2026

    Thanks to over 75 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates and CDMO service. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. Our strong R&D management team, experienced in the development of chemical processes and complex projects, provides a wide range of solutions to our customers, applying a variety of chemical reactions and conditions, including cryogenic, High Pressure, strong base reactions, and tailor-made particle size distribution modifications. At Polpharma quality comes first. Regular FDA audits prove our reliability and credibility towards business partners around the world.